Evidence map›Paper›PMID 33409936›Full record

ReviewDermatology and therapy2021

New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review.

Jane J Han, Adam Faletsky, John S Barbieri, Arash Mostaghimi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dermatology and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. The role of the mineralocorticoid receptor in skin.Molecular and cellular endocrinology · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. New Developments in Topical Acne Therapy.American journal of clinical dermatology · 2022
    Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jane J HanDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7275-8425
Adam FaletskyDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
John S BarbieriDepartment of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
Arash MostaghimiDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA, USA. amostaghimi@bwh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acne vulgaris is a chronic inflammatory skin disease with a multifactorial pathogenesis. Although a variety of acne treatments are available, limitations of current therapies include tolerability, antimicrobial resistance, and costs and patient burden associated with monitoring. This narrative review focuses on emerging treatments and updates on the management of acne. Clascoterone, sarecycline, trifarotene, and novel lotion formulations of tretinoin and tazarotene have been evaluated in clinical trials and provide new options for treatment. Emerging data on the safety and efficacy of spironolactone and isotretinoin challenge current conventions and suggest a need to reconsider drug monitoring guidelines and risk prevention systems. Additional head-to-head data are needed to confirm these novel treatments' utility in treating acne.

Indexed as

AcneClascoteroneIsotretinoinRetinoidsSarecyclineSpironolactone

Identifiers

PMID33409936
PMCPMC7859022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.